Sullender W M
Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, Alabama 35233, USA.
Clin Microbiol Rev. 2000 Jan;13(1):1-15, table of contents. doi: 10.1128/CMR.13.1.1.
Respiratory syncytial virus (RSV) is a major cause of viral lower respiratory tract infections among infants and young children in both developing and developed countries. There are two major antigenic groups of RSV, A and B, and additional antigenic variability occurs within the groups. The most extensive antigenic and genetic diversity is found in the attachment glycoprotein, G. During individual epidemic periods, viruses of both antigenic groups may cocirculate or viruses of one group may predominate. When there are consecutive annual epidemics in which the same group predominates, the dominant viruses are genetically different from year to year. The antigenic differences that occur among these viruses may contribute to the ability of RSV to establish reinfections throughout life. The differences between the two groups have led to vaccine development strategies that should provide protection against both antigenic groups. The ability to discern intergroup and intragroup differences has increased the power of epidemiologic investigations of RSV. Future studies should expand our understanding of the molecular evolution of RSV and continue to contribute to the process of vaccine development.
呼吸道合胞病毒(RSV)是发展中国家和发达国家婴幼儿病毒性下呼吸道感染的主要病因。RSV有两个主要抗原组,A组和B组,且每组内还存在额外的抗原变异性。在附着糖蛋白G中发现了最广泛的抗原和基因多样性。在单个流行期间,两个抗原组的病毒可能同时流行,或者一组病毒可能占主导。当同一组病毒连续多年占主导地位发生年度流行时,每年的优势病毒在基因上都有所不同。这些病毒之间出现的抗原差异可能有助于RSV在一生中引发再次感染。两组之间的差异导致了疫苗开发策略的出现,这些策略应能提供针对两个抗原组的保护。识别组间和组内差异的能力增强了RSV流行病学调查的力度。未来的研究应扩大我们对RSV分子进化的理解,并继续为疫苗开发进程做出贡献。